BSE filing, NSE: JENBURPH. Summary written from the filing by ALFA Finder's alert engine.
Jenburkt Pharmaceuticals Ltd: key numbers
- Share price
- ₹854.00
- Market cap
- ₹376.9 Cr
- Revenue (annual)
- ₹168.7 Cr
- Net profit (annual)
- ₹34.74 Cr
- P/E (TTM)
- 11.5×Sector 45.9×
- Promoter holding
- 46.62%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jenburkt Pharmaceuticals Ltd
All →Jenburkt Pharmaceuticals Board Meeting Date
Jenburkt Pharmaceuticals has intimated that its Board will meet on 3 Nov 2026 to consider Q2/H1-26 financial results. No decision has been taken yet.
Jenburkt Pharmaceuticals Capital Structure Change
Counter Cyclical Investments Private Limited acquired 326 shares of Jenburkt Pharmaceuticals Ltd in the open market, increasing its total shareholding from 4.99% to 5.01%.
Jenburkt Pharmaceuticals Other Announcement
Jenburkt Pharmaceuticals submitted a certificate under SEBI Regulation 74(5) regarding share dematerialization for the quarter ended September 30, 2026.
Jenburkt Pharmaceuticals Other Announcement
Jenburkt Pharmaceuticals clarified its shares are permitted to trade on NSE without a listing application. The shares remain listed on BSE under the Permitted to Trade category.
Jenburkt Pharmaceuticals Management Change
Mr. Vinay Bhatt, Senior Vice President- International Business, has resigned from Jenburkt Pharmaceuticals Limited effective September 18, 2026, due to personal reasons.
Jenburkt Pharmaceuticals Annual General Meeting
Jenburkt Pharmaceuticals held its 41st Annual General Meeting on 4th September, 2026, to discuss financial statements, dividend declaration, and director appointments.
Other debt & borrowing announcements
All →Neogen Chemicals Debt & Borrowing: ₹500 Cr
Neogen Chemicals approved in-principle a Rs 500 Crore corporate guarantee for Neogen Morita's borrowings, subject to shareholder approval. The company reports no adverse impact.
- Value
- ₹500.0 Cr
Satin Creditcare Network Debt & Borrowing: ₹1.83 Cr
Satin Creditcare paid Rs.1.83 Crore quarterly interest on its 10.40% April 2027 NCDs on 31 October 2026. The payment fulfils an existing debt obligation.
- Value
- ₹1.83 Cr
AAA Technologies Debt & Borrowing: ₹6 Cr
AAA Technologies approved an inter-corporate loan of up to Rs.6 Crore to Transaction Solutions International at 12% interest. Repayable on demand; share-pledge security is proposed.
- Value
- ₹6.00 Cr
Spandana Sphoorty Financial Debt & Borrowing: ₹12.5 Cr
Spandana Sphoorty partially redeemed Rs 12.50 Crore of its listed secured NCDs on 31 October 2026 by face-value redemption. Rs 200 Crore remains outstanding.
- Value
- ₹12.50 Cr
Spandana Sphoorty Financial Debt & Borrowing: ₹2.71 Cr
Spandana Sphoorty paid monthly interest of Rs 2.71 Crore across two listed secured NCD series on 30 October 2026, on time. Series-wise amounts were Rs 2.01 Crore and Rs 0.70 Crore.
- Value
- ₹2.71 Cr
Industrial Investment Trust Debt & Borrowing: ₹200 Cr
Industrial Investment Trust's board approved borrowing up to Rs. 200 Crore from banks, NBFCs and other lenders, within the Rs. 1,000 Crore shareholder limit. The enabling approval names no specific lender yet.
- Value
- ₹200.0 Cr